Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD Anderson Cancer Center Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Schroder Family Scholar Post-transplant lymphoproliferative disorders (PTLD) are an aggressive group of lymphomas that occur in the setting of immunosuppression after solid organ transplant. There are very few…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Kanti R. Rai, MD Clinical Scholar Richter’s transformation (RT) represents a devastating progression of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) into an aggressive B-cell lymphoma. Prognosis with RT is…
Researcher Spotlight: Swetha Kambhampati, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Eric Cohen Distinguished Scholar Patients with diffuse large B cell lymphoma (DLBCL) who experience relapse after chimeric antigen receptor (CAR) T cell therapy have limited treatment options, and there…
Researcher Spotlight: Julie Erika Haydu, MD, PhD MASSACHUSETTS GENERAL HOSPITAL Runge Lymphoma Project Scholar Follicular lymphoma (FL) remains an incurable disease with current treatment options. Initial treatment of FL often involves the use of chemotherapy, and there are no approved…
Researcher Spotlight: Daniel Ermann, MD The University of Utah Patients with chronic lymphocytic leukemia (CLL) are at increased risk for infections due to the immune dysfunction associated with the disease. Bacterial pneumonia is a particular concern, and while vaccination with…
Researcher Spotlight: Ayushi Chauhan, MD AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. Stephanie A. Gregory Distinguished Scholar Primary central nervous system lymphoma, or PCNSL, is a rare and aggressive form of non-Hodgkin lymphoma that predominantly affects older adults over the age of…
Researcher Spotlight: Robert Kridel, MD, MPH, PhD UNIVERSITY HEALTH NETWORK, TORONTO Despite therapeutic advances that have transformed the treatment of follicular lymphoma (FL), the disease remains incurable for many patients. Using genomic profiling of tumor samples from large numbers of…
Researcher Spotlight: Arash Alizadeh, MD, PhD Stanford University Although many patients experience profound improvements in disease control with chimeric antigen receptor (CAR) T-cell therapies, not all people with follicular lymphoma (FL) treated with these agents will respond. Using cutting edge…
Researcher Spotlight: Wendy Béguelin, PhD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY Follicular lymphoma (FL) is a clinically heterogenous disease. For some patients, tumors are slow growing and outcomes are favorable; others experience a high-risk, rapidly progressing disease that is associated…